PRODUCT MONOGRAPH

KETOTIFEN OPHTHALMIC SOLUTION

Ketotifen Fumarate Ophthalmic Solution

(0.25 mg/mL as Ketotifen)

Anti-allergy Agent

SteriMax Inc.
1-2735 Matheson Blvd E
Mississauga, ON L4W 4M8

Date of Preparation: January 28, 2013

Submission Control Number: 153118
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 3
  SUMMARY PRODUCT INFORMATION .................................................................. 3
  INDICATIONS AND CLINICAL USE .................................................................. 3
  CONTRAINDICATIONS .................................................................................... 3
  WARNINGS AND PRECAUTIONS .................................................................... 3
  ADVERSE REACTIONS ...................................................................................... 4
  DRUG INTERACTIONS ....................................................................................... 4
  DOSAGE AND ADMINISTRATION .................................................................. 4
  OVERDOSAGE ................................................................................................... 4
  ACTION AND CLINICAL PHARMACOLOGY .................................................... 4
  STORAGE AND STABILITY ............................................................................. 5
  DOSAGE FORMS, COMPOSITION AND PACKAGING ...................................... 5

PART II: SCIENTIFIC INFORMATION ........................................................................... 7
  PHARMACEUTICAL INFORMATION ................................................................. 7
  DETAILED PHARMACOLOGY ......................................................................... 8
  TOXICOLOGY .................................................................................................... 9
  REFERENCES ..................................................................................................... 11

PART III: CONSUMER INFORMATION .................................................................... 12
KETOTIFEN OPHTHALMIC SOLUTION
Ketotifen Fumarate Ophthalmic Solution

PART 1: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical (instillation)</td>
<td>Ophthalmic Solution</td>
<td>Preservative benzalkonium chloride, 0.01%</td>
</tr>
<tr>
<td></td>
<td>0.25 mg/mL as Ketotifen</td>
<td><em>For a complete listing see Dosage Forms, Composition and Packaging section.</em></td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

Ketotifen Ophthalmic Solution is indicated for:
- treatment of allergic conjunctivitis.

CONTRAINDICATIONS

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

WARNINGS AND PRECAUTIONS

**General**

For topical use only. Not for injection or oral use.

As with all ophthalmic preparations containing benzalkonium chloride, patients are advised not to instill Ketotifen Ophthalmic Solution while wearing soft (hydrophilic) contact lenses. Wearers of soft contact lenses should be instructed to remove lenses prior to instillation of drops and to wait at least ten minutes after instilling Ketotifen Ophthalmic Solution before they insert their contact lenses.

To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.

**Special Populations**

**Pregnant Women:** There are no clinical trials on the use of ketotifen fumarate
ophthalmic solution in pregnant or nursing women, therefore, Ketotifen Ophthalmic Solution should not be used during pregnancy, except if the benefit justifies the potential risk to the fetus.

**Pediatrics (>3 years of age):** Ketotifen Ophthalmic Solution is indicated for use in pediatric patients over the age of 3 years.

**ADVERSE REACTIONS**

In controlled clinical studies with ketotifen fumarate ophthalmic solution, conjunctival injection was the most common ocular adverse reaction related to therapy, with a reported incidence of 7.0%. Headache was the most common non-ocular adverse reaction related to therapy, with a reported incidence of 1.5%. The occurrence of these side effects were generally mild and did not result in discontinuation or interruption of trial medication.

The following ocular adverse reactions related to therapy were reported at an incidence of less than 3%.

- Itching, dry eyes, burning or stinging, eyelid disorder and discharge.

**DRUG INTERACTIONS**

If Ketotifen Ophthalmic Solution is used concomitantly with other eye medications, patients should be advised to wait at least 5 minutes between the medications.

**DOSAGE AND ADMINISTRATION**

The recommended dose is one drop in the affected eye(s) every 8 to 12 hours.

**OVERDOSAGE**

For management of a suspected overdose, especially accidental oral ingestion, please contact your regional poison control centre.

Oral ingestion of the contents of a 5 mL bottle would be equivalent to 1.25 mg of ketotifen fumarate. Clinical results have shown no serious signs or symptoms after the ingestion of up to 20 mg of ketotifen fumarate.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

Ketotifen is a fast acting non-competitive histamine antagonist (H1-receptor). In addition,
Ketotifen inhibits the release of mediators from mast cells involved in hypersensitivity reactions. Decreased chemotaxis and activation of eosinophils has also been demonstrated. Additionally, ketotifen attenuates the effects of PAF and inhibits cAMP phosphodiesterase.

In human conjunctival allergen challenge studies, ketotifen fumarate ophthalmic solution was significantly more effective than placebo in preventing ocular itching and redness associated with allergic conjunctivitis. The effect was seen within minutes after administration and lasted up to 12 hours.

**Pharmacodynamics**

In human conjunctival allergen challenge studies, ketotifen fumarate ophthalmic solution was significantly more effective than placebo in preventing ocular itching and redness associated with allergic conjunctivitis. The effect was seen within minutes after administration and lasted up to 12 hours.

In a placebo-controlled clinical study designed to evaluate safety, ketotifen fumarate ophthalmic solution, administered four times a day for 6 weeks, was shown to be safe and well-tolerated in subjects aged 3 years and older.

**STORAGE AND STABILITY**

Store between 4°C and 25°C. Once bottle has been opened for use, discard after 28 days.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

Each mL of Ketotifen Ophthalmic Solution contains:

*Active*: 0.35 mg ketotifen fumarate equivalent to 0.25 mg ketotifen.

*Preservative*: benzalkonium chloride 0.01%

*Inactives*: glycerin, hydrochloric acid/sodium hydroxide and water for injection.

**Packaging:**

Ketotifen Ophthalmic Solution is available in multi-dose white plastic bottles with dropper tips containing 5 mL of clear or faintly yellow solution.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Ketotifen fumarate

Chemical name: 10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one 4,9-dihydro-4-(1-methyl-4-piperidinyl-idene) hydrogen fumarate

Molecular formula: C₁₉H₁₉NOS₁, C₄H₄O₄

Molecular mass: 425.5 g/mol

Structural formula:

![Structural formula image]

Physicochemical properties:

**Description:** white to brownish-yellow, fine crystalline powder.

**Solubility:** sparingly soluble in water, slightly soluble in methyl alcohol, very slightly soluble in acetonitrile.

**Melting point:** Ketotifen fumarate melts between 192°C and 195°C with decomposition.
DETAILED PHARMACOLOGY

Pharmacodynamics

Ketotifen is a benzocycloheptathiophene derivative. Based upon animal pharmacology studies, it exerts anti-anaphylactic and antihistaminic activities, mainly through inhibition of the release of chemical mediators such as histamine and leukotrienes from sensitized mast cells. It also inhibits platelet activating factor (PAF)-induced acute bronchoconstrictor response, airway hyperresponsiveness and accumulation of eosinophils in the airways as well as antigen-induced degranulation of eosinophils in allergic subjects. In addition, ketotifen exhibits a powerful and sustained non-competitive H1-receptor blocking activity distinctly dissociated from its antianaphylactic properties.

The efficacy of ophthalmic solutions of ketotifen fumarate was evaluated by a method utilizing dye leakage in the conjunctiva and/or eyeball following intravenous Evans blue dye. The procedure was originally described as an indicator of accelerated permeability in IgE-mediated conjunctivitis in rats. Ketotifen suppressed dye leakage dose dependently in a model system in which allergic-like effects were induced in the eyes of rats by the single instillation of compound 48/80, which induces the release of histamine and other inflammatory/allergy mediators from mast cells leading to ocular edema. Topical ketotifen ophthalmic solution also resulted in dose dependent inhibition of vascular permeability in passive anaphylactic IgE-mediated conjunctivitis in rats and guinea pigs. These positive effects on IgE-mediated conjunctivitis in rats were also supported by an improved histopathological picture.

Pharmacokinetics

After topical single or repeated administrations of 50 mL drops of approximately 10 mg/mL in albino rabbits, the highest levels of radioactivity were found in the cornea, the conjunctiva, the sclera and the iris, soon after drug administration. In these structures, the experimental T_{max} was 15 minutes, and levels decreased rapidly thereafter. In a whole body autoradiography study in male albino rats, it was shown that the instilled test substance migrated from around the eyes to the nasal and oral cavities via the lacrimal ducts, then to the digestive tract. Tissue migration, other than to the ocular tissues, following ocular instillation, does not differ fundamentally from the distribution following oral administration.

The urinary excretion rate was 9.8% after ocular instillation. This rate was found quite similar to urinary excretion rates after oral (10.5%) or intravenous (13.0%) administrations. In addition, the fecal excretion rate after ocular instillation (83.3%) was not significantly different than the rate after oral (94.0%) or intravenous (82.9%) administration.

After a single topical administration, the highest AUCs were found in the cornea, then the conjunctiva, the iris and the anterior sclera. Levels of ketotifen were 5-14 fold higher in most
tissues 6 hours after multiple topical administrations as compared to the levels after a single administration (except from the plasma and aqueous humor, where a 2-fold rise was observed). The kinetics in blood and plasma after ocular instillation were similar. The half-life was approximately 1.5 hours, while the AUC was 0.3-0.4 mg·hr/mL, and the mean residence time in the body was approximately 3 hours. The mean level was found as low as 0.1-0.2 mg/mL during the steady state with administration at 24-hour intervals.

**Clinical Pharmacology**

In human conjunctival allergen challenge studies, ketotifen fumarate ophthalmic solution was significantly more effective than placebo in preventing ocular itching and redness associated with allergic conjunctivitis. The effect was seen within minutes after administration and lasted up to 12 hours.

In a placebo-controlled clinical study designed to evaluate safety, ketotifen fumarate ophthalmic solution administered four times a day for 6 weeks, was shown to be safe and well-tolerated in subjects aged 3 years and older.

**TOXICOLOGY**

The acute toxicity of ketotifen fumarate has been investigated in mice, rats and rabbits. Oral LD₅₀ values were 165 mg/kg, 360 mg/kg and 790 mg/kg in mice, rats and rabbits, respectively. Subchronic and chronic oral toxicity studies in rats and dogs demonstrated that the liver was a target organ for ketotifen fumarate toxicity. In general, toxicity was observed only after long-term administration of ketotifen fumarate at doses up to 700 times those required to obtain antiallergic and anti-histaminic effects.

In a 4-week ocular toxicity study in rabbits, ketotifen fumarate concentrations of up to 0.267% were classified as practically nonirritating, while 1.104% was considered minimally irritating. In a 13-week ocular study in rabbits, ketotifen fumarate at a concentration of 0.069% was classified as practically nonirritating, while concentrations of 0.276% to 1.104% were classified as minimally irritating. In both studies, histopathological and ultrastructural evaluations revealed no abnormalities in ocular tissue.

A chronic toxicity study was conducted with ketotifen fumarate in albino and pigmented rabbits. Administration of ketotifen fumarate ophthalmic solution 0.025% BID or QID had no effects on mortality, clinical signs, body weight, food consumption, ophthalmoscopic examinations, hematology, clinical chemistry, and urinalysis. No treatment-related findings were observed in gross and histopathological examinations of the tissues and organs particularly on the eye and adnexa.
Carcinogenesis: Ketotifen fumarate demonstrated no carcinogenic effects in lifetime studies in mice and rats at dietary doses more than 70,000 times and 59,000 times the maximum recommended ocular human use level of 0.0012 mg/kg/day for a 50 kg adult respectively.

Mutagenesis: No mutagenic potential was observed when ketotifen fumarate was tested in a battery of in vitro tests including: a bacterial mutation (Ames) test, a bacterial reverse mutation (Ames) test, a mammalian chromosome aberration test and a mutagenicity test in V79 Chinese hamster cells or in the following in vivo tests: a mouse dominant lethal test, a mouse micronucleus test and a Chinese hamster chromosome aberration test on bone marrow cells.

Reproduction and Teratology: There was no evidence of impaired fertility or reproductive capability in studies with ketotifen fumarate in male rats at 8,330 times and in female rats at 41,000 times the maximum recommended ocular human use level. Teratology and peri- and post-natal studies have been conducted with ketotifen fumarate in rats and rabbits. At 80,000 times and 37,000 times the maximum recommended ocular human use level, ketotifen fumarate was shown not to be teratogenic in rats and rabbits respectively and no effects on peri/post-natal development were observed in rats at 37,000 times the maximum recommended ocular human use level.
REFERENCES


PART III: CONSUMER INFORMATION
Ketotifen Ophthalmic Solution
Ketotifen Fumarate Ophthalmic Solution

This leaflet is part III of a three-part "Product Monograph" published when Ketotifen Ophthalmic Solution was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Ketotifen Ophthalmic Solution. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Treatment of seasonal allergic conjunctivitis (itchy, watery, red or swollen eyes and/or eyelids).

What it does:
Ketotifen Ophthalmic Solution is an anti-allergy agent.

When it should not be used:
Do not use Ketotifen Ophthalmic Solution if you are allergic to ketotifen or any of the nonmedicinal ingredients or any component of the container.

What the medicinal ingredient is:
Ketotifen fumarate

What the important nonmedicinal ingredients are:
Benzalkonium chloride, glycerol, hydrochloric acid/sodium hydroxide, water for injection.

What dosage forms it comes in:
White plastic bottles with dropper tips, containing 5 mL of clear or slightly yellow 0.025% ketotifen solution.

INTERACTIONS WITH THIS MEDICATION

If you are using Ketotifen Ophthalmic Solution with any other eye medications, you must wait at least 5 minutes between the use of each medication.

PROPER USE OF THIS MEDICATION

Usual dose:
The usual dose is one drop of Ketotifen Ophthalmic Solution in the affected eye every 8 to 12 hours.
- If you wear contact lenses, you should remove your lenses before using Ketotifen Ophthalmic Solution. Before you put your contact lenses back in, you should wait at least 10 minutes after using Ketotifen Ophthalmic Solution.
- To avoid contamination, do not touch any surface with the tip of the container.

Missed Dose:
If a dose of this medication has been missed, it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular schedule. Do not double doses.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

The most common side effects are red eyes and headache. Other side effects are itching, dry eyes, burning or stinging in the eyes, sore eyelids and discharge from the eyes.

This is not a complete list of side effects. For any unexpected effects while taking Ketotifen Ophthalmic Solution, contact your doctor or pharmacist.

OVERDOSAGE

In case of overdose, especially accidental oral ingestion, contact your health care practitioner (e.g. doctor), hospital emergency department, or regional poison control centre, even if there are no symptoms.

HOW TO STORE IT

Store between 4°C and 25°C. Once the bottle is opened for use, discard after 28 days.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Reporting Form
    Health Canada
    Postal Locator 0701E
    Ottawa, ON K1A 0K9
    Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.
MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:

This leaflet was prepared by SteriMax Inc.

Last revised: Jan 28, 2013.